about
Heart failure guidelines and prescribing in primary care across EuropeThe importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trialsDiffering prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysisAdverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureThe EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatmentRationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular eventsEffect of nesiritide in patients with acute decompensated heart failureAngiotensin-neprilysin inhibition versus enalapril in heart failureIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyEarly treatment with thrombolysis and beta-blockade in suspected acute myocardial infarction: results from the TEAHAT StudyDevelopment of congestive heart failure after treatment with metoprolol in acute myocardial infarctionSeattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study.Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-conveEffect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000.Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis.International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey.Challenges to Data Monitoring Committees When Regulatory Authorities Intervene.Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey.Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases.Skeletal muscle characteristics, muscle strength and thigh muscle area in patients before and after cardiac transplantation.Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.[The long QT interval syndrome as the cause of cardiac syncope]Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry.Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programNeurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.Current and novel pharmacologic approaches in advanced heart failure.Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsRisk stratification for sudden cardiac death: current status and challenges for the futureInfluence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trial.
P50
Q24816665-49A09C98-DDD8-43EA-B885-23F0FB7B4BD6Q27009483-AC911430-400D-4432-87CE-70598FF1949AQ28085643-E49994B8-1D13-4AF3-A292-7D736CB021C4Q28182735-0596937B-EC49-4A6A-B3B5-177F7545EBABQ28192602-8ECABFA4-295E-49DE-BB14-E57BA9B69F04Q28195357-4ED8B01C-1723-4406-8C48-FB5178E7CB9BQ28219191-D68E1F69-E14D-4306-9B84-4D5DBF3A7C6CQ28242547-5B2D2C08-7E75-4BF3-A1B0-B5A6994FDD28Q28247091-A19DCF3C-DD4B-4FEB-9E77-3824B4981C33Q28291971-2D3A81F4-24AE-435D-89AA-C70999DA2EC6Q28333275-7CC6E002-AA5A-4C9B-ACA7-792961AA135AQ28366447-76AAA5E5-34D2-4642-873A-77492B841F4CQ30252338-295792E7-1C15-46A5-9235-10C5AF70330DQ30405473-2FABD3BB-ACB1-4DF0-AE4B-4B7DEC65B2C8Q30597068-942BA034-3414-4874-9895-FE8AA6CB53E7Q30608315-CE9ED2CD-20D5-469B-AB76-F03C783589A0Q30664916-E0D3D8D3-A163-4AF5-AB97-421B6C8B30E9Q30686199-CE329837-6910-44F8-8DAB-992B342DCAD6Q30908516-DF703A0E-F8A6-4547-BDFB-B54F0CEEB540Q30952502-117F495C-F481-4427-A2C3-306BDD5183D9Q31064781-101F0177-2E97-45AF-BBA8-BA42AC5AD497Q31068199-6C69E421-A1C0-4F4D-808E-25F37AE3D718Q31094492-B5EEEAA2-0D4E-4BD9-8EE2-83BAB2149C2CQ31106553-13DE4228-9A10-4F17-B774-FAABE4A98D5FQ31115364-45C12170-30F5-4803-A594-7DFD9BA62D05Q31117253-5B4FC96C-92DB-4059-9703-B65F934844C6Q31172477-BFEA1BA6-1501-4DCF-AE84-1DA6997746D5Q31863963-9D04C83F-D525-415E-A1E2-B9095BFAB3B5Q31863980-85A01972-5353-4468-8EA9-D5FF7B8B602AQ33169387-A1FA1A83-FAFF-4CA5-936B-50BC08400E24Q33395934-12B3C73C-B2F2-4CD7-8AB2-B0121C174C8BQ33402824-461B986D-4E26-41CE-AB0A-F6B71815E893Q33614319-474E1797-2DAD-4D90-ACB4-EF4EB5D6F6ABQ33688965-61840E30-737E-40A1-8744-1476668D80BCQ33711285-D5368F94-EF77-4A75-A6DF-A5C514584795Q33768602-6F4C1D43-BE45-40BA-AFF5-034F6DE1F576Q33827123-49DDA3DF-7694-4719-BD86-7A9FF6D15501Q33916711-A6CB5C86-03C6-4415-827D-1A51F4B009E0Q34003169-85133EA5-39B3-4E86-8E50-BCFB1D3C627FQ34019737-D69E2535-C22E-44DC-8E00-4C927860E2E5
P50
description
Swedish professor
@en
Zweeds professor
@nl
catedràtic suec
@ca
catedrático sueco
@es
katedradun suediarra
@eu
ollamh Sualannach
@ga
profesor sueco
@gl
profesor suecu
@ast
professeur suédois
@fr
professor sueco
@pt
name
Karl Swedberg
@ast
Karl Swedberg
@da
Karl Swedberg
@de
Karl Swedberg
@en
Karl Swedberg
@es
Karl Swedberg
@fr
Karl Swedberg
@ga
Karl Swedberg
@nb
Karl Swedberg
@nl
Karl Swedberg
@nn
type
label
Karl Swedberg
@ast
Karl Swedberg
@da
Karl Swedberg
@de
Karl Swedberg
@en
Karl Swedberg
@es
Karl Swedberg
@fr
Karl Swedberg
@ga
Karl Swedberg
@nb
Karl Swedberg
@nl
Karl Swedberg
@nn
prefLabel
Karl Swedberg
@ast
Karl Swedberg
@da
Karl Swedberg
@de
Karl Swedberg
@en
Karl Swedberg
@es
Karl Swedberg
@fr
Karl Swedberg
@ga
Karl Swedberg
@nb
Karl Swedberg
@nl
Karl Swedberg
@nn
P214
P106
P21
P214
P27
P31
P496
0000-0002-6358-2154
P735
P7859
lccn-nb2002082152